Source:http://linkedlifedata.com/resource/pubmed/id/15187431
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2004-6-9
|
| pubmed:abstractText |
A series of ethacrynic acid (ECA) derivatives were synthesized and examined for ocular hypotensive activity. Efficacy was evaluated in a cell-shape assay, using human trabecular meshwork cells, and cytotoxicity in a (3-(4,5-dimethylthiazole-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, using cultured bovine trabecular meshwork cells. Many of the derivatives demonstrated efficacy equal to or greater than that of ECA. SA9000 was selected as the most promising candidate for a novel ocular hypotensive drug with few side effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0918-6158
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
846-50
|
| pubmed:meshHeading | |
| pubmed:year |
2004
|
| pubmed:articleTitle |
New ethacrynic acid derivatives as potent cytoskeletal modulators in trabecular meshwork cells.
|
| pubmed:affiliation |
Research and Development Center, Santen Pharmaceutical Co. Ltd., Takayama, Ikoma, Japan. shimazaki@snaten.co.jp
|
| pubmed:publicationType |
Journal Article
|